Show simple item record

dc.contributor.authorvan der Graaf, WTAen_US
dc.contributor.authorTielen, Ren_US
dc.contributor.authorBonenkamp, JJen_US
dc.contributor.authorLemmens, Ven_US
dc.contributor.authorVerhoeven, RHAen_US
dc.contributor.authorde Wilt, JHWen_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2019-03-05T16:38:49Z
dc.date.issued2018-07en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/29664995en_US
dc.identifier.citationBr J Surg, 2018, 105 (8), pp. 1020 - 1027en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3139
dc.identifier.eissn1365-2168en_US
dc.identifier.doi10.1002/bjs.10809en_US
dc.description.abstractBACKGROUND: The incidence, treatment and outcome of patients with newly diagnosed gastrointestinal stromal tumour (GIST) were studied in an era known for advances in diagnosis and treatment. METHODS: Nationwide population-based data were retrieved from the Netherlands Cancer Registry. All patients with GIST diagnosed between 2001 and 2012 were included. Primary treatment, defined as any treatment within the first 6-9 months after diagnosis, was studied. Age-standardized incidence was calculated according to the European standard population. Changes in incidence were evaluated by calculating the estimated annual percentage change (EAPC). Relative survival was used for survival calculations with follow-up available to January 2017. RESULTS: A total of 1749 patients (54·0 per cent male and median age 66 years) were diagnosed with a GIST. The incidence of non-metastatic GIST increased from 3·1 per million person-years in 2001 to 7·0 per million person-years in 2012; the EAPC was 7·1 (95 per cent c.i. 4·1 to 10·2) per cent (P < 0·001). The incidence of primary metastatic GIST was 1·3 per million person-years, in both 2001 and 2012. The 5-year relative survival rate increased from 71·0 per cent in 2001-2004 to 81·4 per cent in 2009-2012. Women had a better outcome than men. Overall, patients with primary metastatic GIST had a 5-year relative survival rate of 48·2 (95 per cent c.i. 42·0 to 54·2) per cent compared with 88·8 (86·0 to 91·4) per cent in those with non-metastatic GIST. CONCLUSION: This population-based nationwide study found an incidence of GIST in the Netherlands of approximately 8 per million person-years. One in five patients presented with metastatic disease, but relative survival improved significantly over time for all patients with GIST in the imatinib era.en_US
dc.format.extent1020 - 1027en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectAdolescenten_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectAntineoplastic Agentsen_US
dc.subjectDigestive System Surgical Proceduresen_US
dc.subjectFemaleen_US
dc.subjectGastrointestinal Stromal Tumorsen_US
dc.subjectHumansen_US
dc.subjectImatinib Mesylateen_US
dc.subjectIncidenceen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectNetherlandsen_US
dc.subjectRegistriesen_US
dc.subjectSurvival Rateen_US
dc.titleNationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era.en_US
dc.typeJournal Article
dcterms.dateAccepted2017-11-28en_US
rioxxterms.versionofrecord10.1002/bjs.10809en_US
rioxxterms.licenseref.startdate2018-07en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfBr J Surgen_US
pubs.issue8en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma
pubs.publication-statusPublisheden_US
pubs.volume105en_US
pubs.embargo.termsNot knownen_US
icr.researchteamClinical and Translational Sarcomaen_US
dc.contributor.icrauthorvan der Graaf, Wilhelminaen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/